This New Medicare Pilot Program Offers GLP-1s For $50 A Month. Here’s What You Need To Know
Medicare has launched a new pilot program called Bridge that allows eligible beneficiaries to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month, a dramatic reduction from hundreds of dollars. However, the program faces implementation challenges and is only guaranteed through the end of 2027, creating uncertainty for patients starting long-term therapies.
Summary
Starting this week, millions of eligible Medicare patients gain access to GLP-1 obesity drugs through a new federal pilot program called Bridge, marking a significant shift in Medicare policy. Traditionally, Medicare has barred coverage of medications prescribed solely for obesity, but this program creates a temporary pathway for coverage. Eligible beneficiaries must meet certain requirements, including a BMI over 35 and the presence of certain obesity-related conditions, and can access these medications for a $50 monthly copay instead of the typical hundreds of dollars per month. This move could potentially reach as many as 20 million new patients according to Novo Nordisk and Eli Lilly's estimates, with officials expecting several million beneficiaries to enroll immediately. The program addresses a significant access gap for older Americans who have been unable to afford these popular weight loss drugs. However, the rollout faces practical challenges. Doctors must submit prior authorization requests to confirm patient eligibility before coverage is approved, and physicians are concerned that an influx of new patients could strain already busy clinics and pharmacies. More critically, the coverage is not permanent—unless the Trump administration extends or replaces the program, Bridge coverage is scheduled to expire by the end of 2027, and any permanent changes would require congressional approval. This creates a significant risk for patients who will begin long-term obesity therapies without knowing whether coverage will continue beyond 2027.
Key Insights
- GLP-1 obesity drugs have cost hundreds of dollars per month, making them out of reach for most older Americans on Medicare until this week's program launch
- The Bridge program represents a major shift because Medicare has traditionally barred coverage of medications prescribed solely for obesity
- Novo Nordisk and Eli Lilly estimate the program could reach as many as 20 million eligible patients, with several million expected to enroll immediately
- Physicians warn that a wave of new patients could put additional pressure on already busy clinics and pharmacies over the next couple of months
- The coverage through Bridge is scheduled to expire by the end of 2027 unless the Trump administration extends it, and permanent changes would require congressional approval
Topics
Transcript
[0:00] Popular weight loss drugs have remained out of reach for most older Americans in Medicare for years. That's because GLP-1s can cost hundreds of dollars per month, but that changes this week. Starting Wednesday, millions of eligible Medicare patients can access GLP-1 obesity drugs >> [music] >> from Novo Nordisk and Eli Lilly for a copay of just $50 per month. It's a major shift for a federal program that has traditionally barred coverage of medications prescribed solely for obesity. So, what happened? Well, there's a new Medicare pilot program called Bridge that's creating a temporary pathway for coverage. Patients [0:31] who meet [music] certain requirements, including those with a BMI of over 35 and people with certain obesity-related…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
Why Warner Records is investing in South Asian artists
South Asian music is experiencing rapid mainstream growth in the US, driven by streaming platforms that enable global access. Warner Records and industry leaders recognize this as a pivotal moment for South Asian artists, with Indian artists seeing over 2000% stream growth in international markets and generating 50% of their platform royalties from outside India.
Why Americans Are Buying Cheaper Diamonds
Lab-grown diamonds have disrupted the traditional diamond market, accounting for 61% of U.S. engagement ring sales in 2026 and causing natural diamond prices to plunge 60% in five years. Major industry players like De Beers are struggling to adapt as lab-grown stones offer lower prices, lower environmental impact, and ethical advantages over mined diamonds.
Inside China’s Race To Build The World’s Data Centers
China's prefabricated data center manufacturing offers a significant speed advantage over U.S. construction, potentially reducing build times from 2-3 years to 9 months, while the U.S. becomes increasingly dependent on Chinese supply chains despite geopolitical tensions and national security concerns.
How Williams-Sonoma Became One Of Retail’s Best-Performing Stocks
Williams-Sonoma has outperformed the S&P 500 and competitors by leveraging its omnichannel model, focusing on full-price selling to affluent customers, and deploying AI to enhance e-commerce and supply chain efficiency. Despite a sluggish housing market, the company has achieved margin expansion and is pursuing growth opportunities through smaller home furnishings, B2B expansion, and renewed store openings.
Why It’s So Hard To Build An AI Kill Switch
The video explores whether an AI kill switch is technically feasible and practically implementable. While experts acknowledge the need for safety mechanisms, they conclude that a single universal kill switch is impossible due to distributed computing infrastructure, and that comprehensive regulation similar to other industries would be more effective than a technological quick fix.